Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) tinted loss of -0.87% (-0.24 points) to US$27.44. The volume of 0.36 Million shares climbed down over an trading activity of 707.47 Million shares. EPS ratio determined by looking at last 12 month figures is -5.67. Over the same time span, the stock marked US$44 as its best level and the lowest price reached was US$13.5. The corporation has a market cap of US$744.17 Million.
Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS)’s earnings per share has been growing at a -46.3 percent rate over the past 5 year when average revenue increase was noted as -56.7 percent. The return on equity ratio or ROE stands at -101.9 percent while most common profitability ratio return on investment (ROI) was -65.9 percent. The company’s institutional ownership is monitored at 0 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 98.7 percent gross margin.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 4 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 0 think it is Hold. Recently, analysts have updated the overall rating to 1.64. 7 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.
Insmed Incorporated (NASDAQ:INSM) is worth US$2.3 Billion and has recently fallen -0.87% to US$28.55. The latest exchange of 0.29 Million shares is below its average trading activity of 691.34 Million shares. The day began at US$28.84 but the price moved to US$28.38 at one point during the trading and finally capitulating to a session high of US$29.26. The stock tapped a 52-week high of US$33.94 while the mean 12-month price target for the shares is US$38.44.
Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 5.03, and a price to sales ratio of 0. For the past 5 years, the company’s revenue has grown 0%, while the company’s earnings per share has grown -13.2%. With an institutional ownership near 0%, it carries an earnings per share ratio of -3.16.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 2 brokerage firms polled by Factset Research. At present, 1 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 6 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 1.89.